ARTICLE | Market Access
Moderna looks to subscriptions as future of vaccine business
The goal is to get countries to sign 10-year contracts for pre-specified volumes
February 26, 2022 1:08 AM UTC
Moderna’s planned subscription model for its future pan-respiratory vaccine deviates from the path charted by anti-infectives by maintaining a focus on volume.
In addition to reporting a share buyback and returned KRAS vaccine in an earnings presentation Thursday, Moderna Inc. (NASDAQ:MRNA) CEO Stéphane Bancel said the company wants to “create a new business model with governments,” wherein participating countries sign up for a 10-year subscription for a pre-specified number of doses of a pan-respiratory annual booster...
BCIQ Company Profiles